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Abstract
Background: Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been suggested to play a role
in a subset of patients with neuromyelitis optica and related disorders.
Objective: To assess (i) the frequency of MOG-IgG in a large and predominantly Caucasian cohort of patients with
optic neuritis (ON) and/or myelitis; (ii) the frequency of MOG-IgG among AQP4-IgG-positive patients and vice versa;
(iii) the origin and frequency of MOG-IgG in the cerebrospinal fluid (CSF); (iv) the presence of MOG-IgG at disease
onset; and (v) the influence of disease activity and treatment status on MOG-IgG titers.
Methods: 614 serum samples from patients with ON and/or myelitis and from controls, including 92 follow-up
samples from 55 subjects, and 18 CSF samples were tested for MOG-IgG using a live cell-based assay (CBA) employing
full-length human MOG-transfected HEK293A cells.
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Results: MOG-IgG was detected in 95 sera from 50 patients with ON and/or myelitis, including 22/54 (40.7 %) patients
with a history of both ON and myelitis, 22/103 (21.4 %) with a history of ON but no myelitis and 6/45 (13.3 %) with a
history of longitudinally extensive transverse myelitis but no ON, and in 1 control patient with encephalitis and a
connective tissue disorder, all of whom were negative for AQP4-IgG. MOG-IgG was absent in 221 further controls,
including 83 patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and 85 with multiple
sclerosis (MS). MOG-IgG was found in 12/18 (67 %) CSF samples from MOG-IgG-seropositive patients; the MOG-IgG-
specific antibody index was negative in all cases, indicating a predominantly peripheral origin of CSF MOG-IgG.
Serum and CSF MOG-IgG belonged to the complement-activating IgG1 subclass. MOG-IgG was present already at
disease onset. The antibodies remained detectable in 40/45 (89 %) follow-up samples obtained over a median period
of 16.5 months (range 0–123). Serum titers were higher during attacks than during remission (p < 0.0001), highest
during attacks of simultaneous myelitis and ON, lowest during acute isolated ON, and declined following treatment.
Conclusions: To date, this is the largest cohort studied for IgG to human full-length MOG by means of an up-to-date
CBA. MOG-IgG is present in a substantial subset of patients with ON and/or myelitis, but not in classical MS. Co-
existence of MOG-IgG and AQP4-IgG is highly uncommon. CSF MOG-IgG is of extrathecal origin. Serum MOG-IgG is
present already at disease onset and remains detectable in the long-term course. Serum titers depend on disease
activity and treatment status.
Keywords: Neuromyelitis optica (NMO), Devic’s syndrome, Optic neuritis, Transverse Myelitis, Longitudinally extensive
transverse myelitis (LETM), Neuromyelitis optica spectrum disorders (NMOSD), Multiple sclerosis, Autoantibodies, Myelin
oligodendrocyte glycoprotein antibodies (MOG-IgG), Neuromyelitis optica antibodies (NMO-IgG), Aquaporin-4
antibodies (AQP4-IgG), Cell-based assays, Cerebrospinal fluid, Antibody index
Background
Neuromyelitis optica (NMO) is a severely disabling auto-
immune disorder of the CNS. In the majority of cases,
NMO is caused by autoantibodies to aquaporin-4 (AQP4-
IgG) [1–6]; however, 10–20 % of patients with NMO are
negative for AQP4-IgG [7–11]. Back in 2007, based on
preliminary results, we and others suggested a potential role
for IgG antibodies to myelin oligodendrocyte glycoprotein
(MOG-IgG) in AQP4-IgG-seronegative NMO. At that time,
however, MOG-IgG were still detected by enzyme-linked
immunosorbent assays (ELISA) or immunoprecipitation
assays, methods that were not always reliable [12], and
skepticism prevailed. The following years saw the rise of
so-called cell-based assays (CBA) for the detection of auto-
antibodies. CBA have shown excellent sensitivity and specifi-
city in many applications, including AQP4-IgG testing [8, 9].
Briefly, cultured human cells (mostly HEK293 cells) are
transfected with the antigen of interest not constitutively
expressed in those cells and used as antigenic substrate in
an indirect immunofluorescence assay; mock-transfected
cells are used as internal controls. According to a recent
consensus statement, CBA are currently considered the best
method for detecting AQP4-IgG in NMO [9, 13]. Moreover,
assays for detecting conformation-sensitive antibodies to
MOG were devised. By the use of such assays, several
groups have demonstrated antibodies to MOG in mostly
pediatric patients with ADEM or MS-like disease [14–16].
Later on, in a study published in this journal in 2011, some
of us demonstrated antibodies to full-length MOG in patients
with NMO for the first time by means of a CBA [17]. In the
meantime, several studies by us and others have confirmed
the association of MOG-IgG with NMO and with related
disorders such as isolated optic neuritis (ON) or myelitis
[18–28]. Most studies have found MOG-IgG exclusively in
patients with ON and/or myelitis who are negative for
AQP4-IgG, suggesting that MOG-IgG may denote a disease
entity in its own right. The latter notion is further supported
by recent in vitro and in vivo studies suggesting a direct
pathogenic role of MOG-IgG [17, 29] and by studies demon-
strating substantial differences in the histopathology of
AQP4-IgG- and MOG-IgG-associated CNS lesions [30–33].
However, there were some obvious limitations: First,
many of the previously investigated cohorts were rela-
tively small. Second, long-term data were often absent,
with follow-up samples not being available. Third, some
cohorts included no Caucasian patients or were genetic-
ally mixed, which may be of relevance since genetic
factors are thought to play a role in NMO [34]. Fourth,
some cohorts were preselected according to AQP4-IgG
serostatus. Fifth, control groups in some previous studies
were formally too small to assess the specificity of anti-
body results in a reliable way. Sixth, these last two limita-
tions prompt uncertainty about the prevalence of the rare
so-called ‘double-positive’ samples, i.e., samples positive
for both NMO-IgG and AQP4-IgG, that have been re-
ported in a few studies [17, 22, 35]. Finally, most previous
investigations have focused on serum and included no or
only few cerebrospinal fluid (CSF) samples.
In the present study we assessed the frequency of
MOG-IgG as assessed by means of a live-cell CBA [17]
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(i) in a large series of samples from predominantly
Caucasian patients sent in for AQP4-IgG and MOG-IgG
testing and (ii) in a well-defined cohort of Caucasian
control patients with multiple sclerosis (MS) and other
inflammatory CNS disorders as well as in healthy controls
(N = 614). In addition, we evaluated (iii) the prevalence of
MOG-IgG and AQP4-IgG double positivity based on a
very large number of samples (N = 459); (iv) the presence
of MOG-IgG at disease onset; (v) the long-term persist-
ence of MOG-IgG in individual patients; (vi) the influence
of disease activity and treatment status on MOG-IgG
titers; and (vii) the frequency and origin of MOG-IgG
antibodies in the CSF.
This study is part of an article series on MOG-IgG in
CNS inflammation. In part 2, we systematically evaluate
the clinical and paraclinical features present in MOG-
IgG-positive ON and/or myelitis as well as treatment re-
sponses and long-term outcome [36]. In part 3, we
analyze the clinical and radiological features, course, and
prognosis of patients with MOG-IgG-associated brain-
stem encephalitis [37]. In part 4, we report on the fre-
quency and severity of afferent visual nerve damage in
MOG-IgG-associated ON as detected by retinal optical
coherence tomography (OCT) [38].
Methods
In total, 614 serum samples and 18 CSF samples from
522 subjects were tested for MOG-IgG. Group I comprised
386 serum samples from 300 patients referred for routine
MOG-IgG testing by 11 European academic centers,
including the departments of neurology at the University
of Heidelberg, the Charité-University Medicine Berlin, the
University of Düsseldorf, the University of Bochum,
Hannover Medical School, the University of Würzburg,
the University of Rostock, the University of Freiburg, all in
Germany; the University of Southern Denmark, Denmark;
the MS Center at the Azienda Ospedaliero Universitaria
San Luigi Gonzaga, Orbassano, Italy; and the IRCCS, C.
Mondino National Neurological Institute, Pavia, Italy; eight
of which are members of the German Neuromyelitis optica
Study Group (NEMOS). Samples were taken for routine
clinical assessment. Diagnoses at the time of blood
sampling as reported by the referring centers, all of which
were tertiary care university hospitals with specialized
neuroimmunological departments, included “ON and
myelitis” in 54 patients (1 x AQP4-IgG-positive; 79 serum
samples available for testing), “monophasic ON” in 66 (69
samples), “recurrent ON” in 37 (median number of ON
attacks 4, range 2–15; 76 samples), “longitudinally exten-
sive transverse myelitis” in 45 (57 samples), “relapsing
remitting MS” (RRMS) in 50 (54 samples), “secondary
progressive MS” (SPMS) in 2 (2 samples), “primary
progressive MS” (PPMS) in 2 (2 samples), and “other
neurological disorder” (OND) in 44 (47 samples).
Group II consisted of 89 anonymized serum samples
from 83 control patients with AQP4-IgG-positive ON
and/or myelitis. Of those, 56 had a history of ON and
myelitis, 22 of myelitis but no ON, and 5 of ON but no
myelitis. AQP4-IgG had been previously detected by use
of a commercial CBA (Euroimmun, Lübeck, Germany)
in these patients [8] and by means of an ELISA (RSR,
Cardiff, UK) [10].
Group III was made up of 85 anonymized serum
samples from 85 control patients with MS according to the
McDonald criteria (RRMS in 73, SPMS in 9, PPMS in 3).
Group IV comprised 54 anonymized samples from 9
control patients with OND (including 8 with connective
tissue disorders and brain involvement [39]) and from
45 healthy controls.
Ninety-two follow-up samples (86 × group I, 6 × controls)
from 55 subjects were tested. The sex ratios (m:f) were
1:2.4 in group I and 1:3 in the control groups II–IV. The
median age was 39 years in group I and 38 years among the
control patients (groups II–IV). See Table 1 for additional
demographic data. 516/522 (98.9 %) tested subjects were of
Caucasian descent, including 298/300 (99.3 %) in group I.
All sera were tested using a live-cell CBA employing
HEK293A cells transfected with full-length human MOG
as previously described [17]. Screening of serum samples
was performed at dilutions of 1:20 and 1:40, and antibody
titers of positive serum samples were determined by serial
dilutions. MOG-antibody titers of ≥1:160 were classified
as seropositive [17]. If samples were tested more than
once, the highest titer obtained with each sample was used
for analysis in all control groups to ensure that data on
assay specificity were as conservative as possible. Low-
titer results (1:160–1:320) were confirmed in a second,
methodologically independent CBA employing formalin-
fixed HEK293 cells transfected with full-length human
MOG (Euroimmun). CSF samples were screened un-
diluted, and antibody titers of positive samples were
determined by serial dilutions (1:2, 1:4, etc.). The control
samples were tested with MOG-IgG-positive serum
samples interspersed. MOG-IgG serostatus and titers were
determined by two independent investigators blinded to
all clinical data (M.R., K.S.). To assess the origin of CSF
MOG-IgG, the MOG-specific antibody index (AIMOG)
was determined. Calculation of AIs allows quantification
of antigen-specific intrathecal antibody synthesis [40–43].
Briefly, AIMOG values were calculated as the ratio between
the CSF/serum quotient for MOG-IgG, QMOG-IgG, and the
CSF/serum quotient for total IgG, QIgG(total), or Qlim, if
QIgG(total) exceeded Qlim; i.e., AIMOG=QMOG-IgG/QIgG(total), if
QIgG(total) <Qlim, and AIMOG=QMOG-IgG/Qlim, if QIgG(total) >
Qlim. CSF and serum samples were obtained at the same
time. Usually, values >1.5 are considered as evidence of
intrathecal specific antibody synthesis [40, 41]. However, if
titers instead of concentrations are used to calculate the AI, a
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cut-off value of 4 has been recommended [44].
Reiber’s empiric hyperbolic function Qlim was applied
to control for possible underestimation of intrathecal
specific synthesis due to disturbances of the blood-CSF
barrier function and was calculated as follows [45]:
QlimðIgGÞ ¼ 0:93
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
QAlbð Þ2 þ 6 106
q
−1:7 103
The study was approved by the institutional review boards
of the participating centers and patients gave their informed
consent for publication of clinical data. The control samples
were tested in anonymized fashion as requested by the insti-
tutional review board of the University of Heidelberg. The
Mann-Whitney U test was used to compare antibody titers
between groups, and the Kruskal-Wallis test with Dunn’s
post test to compare more than two groups. Differences
with P values <0.05 were considered statistically significant.
Results
Frequency of serum MOG-IgG and syndrome specificity
Overall, 96/614 (15.6 %) samples and 51/522 (9.8 %) sub-
jects were positive for MOG-IgG (Figs. 1 and 2). In group
I (samples sent in for routine assessment of MOG-IgG),
MOG-IgG was detected in 95/386 (24.6 %) samples from
50/300 (16.7 %) patients; if only patients with a diagnosis
of ON and/or myelitis are considered, MOG-IgG was
present in 95/281 (33.8 %) samples from 50/202 (24.8 %)
patients. In group II (AQP4-IgG-positive controls), none
of 89 samples from 83 patients was positive for MOG-
IgG. MOG-IgG was also absent in 85 samples from
85 patients in group III (MS control samples). In group
IV (OND and healthy controls), 1/54 (1.9 %) samples from
1/54 (1.9 %) patients was positive for MOG-IgG (Fig. 2).
In total, MOG-IgG was present in 1 of 228 (0.4 %) control
samples or 1 of 222 (0.5 %) control patients (p < 0.0001 for
group I patients vs groups II–IV patients).
All MOG-IgG-positive patients in group I had a history
of ON and/or myelitis (Table 1, Fig. 3); 22/50 (44 %) had a
history of both ON and myelitis; 22/50 (44 %) had a history
of ON but not of myelitis (recurrent in 13); and 6/50 (12 %)
had a history of longitudinally extensive myelitis (LETM)
but not of ON. The relative frequencies of MOG-IgG in
group I patients with a history of ON and myelitis, myelitis
but not ON, and ON but not myelitis, respectively, were
22/54 (40.7 %), 22/103 (21.4 %), and 6/45 (13.3 %). All of
Table 1 Demographic and serological findings from 522 subjects and 614 serum samples tested for MOG-IgG
Diagnostic categories Sample
numbers
Patient
numbers
Sex ratio
(m:f)
Age (ys),
median
MOG-IgG+,
samples
MOG-IgG+,
patients
MOG-IgG+,
median§
AQP4-IgG +,
MOG-IgG + patients
Group I 386 300 1:2.4 39 95/386 (24.6 %) 50/300 (16.7 %) 1:640 0/50 (0 %)
“ON and/or MY”a 281 202 95/281 (33.8 %) 50/202 (24.8 %) 1:640 0/50 (0 %)
“ON and MY”a 79 54 39/79 (49.4 %) 22/54 (40.7 %) 1:1280 0/22 (0 %)
“mON/rON”a 145 103 47/145 (32.4 %) 22/103 (21.4 %) 1:640 0/22 (0 %)
“mON”a 69 66 10/69 (14.5 %) 9/66 (13.6 %) 1:800 0/9 (0 %)
“rON”a 76 37 37/76 (48.7 %) 13/37 (35.1 %) 1:640 0/13 (0 %)
“MY” (all LETM)a 57 45 9/57 (15.8 %) 6/45 (13.3 %) 1:2560 0/6 (0 %)
“MS”a 58 54 0/58 (0 %) 0/54 (0 %) N.a. N.a.
“OND”a 47 44 0/47 (0 %) 0/44 (0 %) N.a. N.a.
Group II 89 83 1:1.9 46 0/89 (0 %) 0/83 (0 %) N.a. 89/89 (100 %)
AQP4+ NMO 59 56 0/59 (0 %) 0/56 (0 %) N.a. 59/59 (100 %)
AQP4+ rON 5 5 0/25 (0 %) 0/22 (0 %) N.a. 25/25 (100 %)
AQP4+ LETM 25 22 0/5 (0 %) 0/5 (0 %) N.a. 5/5 (100 %)
Group III 85 85 1:3 38 0/85 (0 %) 0/85 (0 %) N.a. N.a.
RRMS 73 73 0/73 (0 %) 0/73 (0 %) N.a. N.a.
SPMS 9 9 0/9 (0 %) 0/9 (0 %) N.a. N.a.
PPMS 3 3 0/3 (0 %) 0/3 (0 %) N.a. N.a.
Group IV 54 54 1:1.3 38 1/54 (1.9 %) 1/54 (1.9 %) 1:320* 0/1 (0 %)
OND 9 9 1/9 (11.1 %) 1/9 (11.1 %) 1:320* 0/1 (0 %)
HC 45 45 0/45 (0 %) 0/45 (0 %) N.a. N.a.
Group II–IV 228 222 1:1.9 38 1/228 (0.5 %) 1/222 (0.5 %) 1:320* 0/1 (0 %)
Total 614 522 1:2.6 38 96/614 (15.6 %) 51/522 (9.8 %) 1:640 0/51 (0 %)
N.a not applicable, ON optic neuritis, mON monophasic ON, rON recurrent ON, MY myelitis, LETM longitudinally extensive transverse myelitis, MS multiple sclerosis,
OND other neurological disorders, RRMS relapsing remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, HC healthy control. aSuspected
diagnosis at the time of sample referral. §MOG-IgG-positive samples only. *Single patient
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the MOG-IgG-positive patients were negative for AQP4-
IgG. Detailed clinical, radiological, electrophysiological, and
laboratory data as well as data on treatment responses and
outcome are reported in parts 2, 3 and 4 of this series
[36–38]. Moreover, detailed case reports can be found in
the Appendix sections of part 2 [36] and part 3 [37].
The only positive control sample was a low-titer sample
(1 × 1:320, re-testing: 1 × 1:160) obtained from an OND pa-
tient from group IV originally diagnosed with systemic lupus
erythematosus (American College of Rheumatology criteria
met) and “leukoencephalitis of unknown origin”. Symptoms
included “scotoma”, “seizures” and “depression”; the sample
was negative when tested in the fixed-cell CBA used to con-
firm the other low titer samples, suggesting a possible false-
positive result. As the control samples were analyzed in
anonymized fashion, no more data were available on this
case. By contrast, 11 further samples from 11 patients with
CNS symptoms and systemic lupus erythematosus or other
connective tissue disorders included in groups I and IV were
negative for MOG-IgG. Follow-up samples were available
from 6 MOG-IgG-negative control patients (groups II–IV),
all of which were also negative for MOG-IgG.
Co-existence of MOG-IgG and AQP4-IgG
None of the 51 MOG-IgG-positive group I and IV pa-
tients was positive for AQP4-IgG, and none of 84
AQP4-IgG-positive patients from groups II and I was
positive for MOG-IgG (Table 1). AQP4-IgG was tested
in MOG-IgG-positive patients using a standardized
commercial CBA [8] in 48 (94 %) and by ELISA [10] in
3 (6 %). In addition, 226 patients from group I and 98
control patients from groups III and IV were negative
both for MOG-IgG and for AQP4-IgG. Overall, 459 pa-
tients were tested for both MOG-IgG and AQP4-IgG.
MOG-IgG serum titers
If all seropositive samples are considered, MOG-IgG ti-
ters in group I as determined in the live CBA ranged be-
tween 1:160 and 1:20480. If only the highest titer sample
in each patient is considered, the median titer in group I
was 1:1280 (range 160–20480; N = 50); maximum titres
were higher in patients with a history of myelitis (me-
dian 1:2560, range 160-20480; N=7) or a history of both
myelitis and ON (1:1280; range 160-10240; N=22) at last
follow-up than in patients with a history of ON but no
Fig. 1 MOG-IgG as detected by two independent cell-based assays (CBA): typical findings. a, b Binding of serum IgG from a group I patient (a)
but not from a control patient (b) to live HEK293A cells transfected with human full-length MOG. c, d Binding of serum IgG from a group I patient
to formalin-fixed HEK293 cells transfected with full-length MOG (c) but not to their mock-transfected counterpart (d) in a commercial CBA. Bound
MOG-IgG was visualized in the live-cell assay using a Cy3-conjugated goat anti-human IgG antibody and in the fixed-cell assay by use of a fluorescein
isothiocyanate (FITC)-labeled goat anti-human IgG antibody
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myelitis at last follow-up (1:640; range 160-20480;
N=21), but the difference did not reach statistical
significance.
Presence of serum MOG-IgG at disease onset
MOG-IgG was present already at disease onset in all
patients with available data: 2 MOG-IgG positive sera
were taken within the first week (at 2 and 4 days)
after disease onset, 10 within the first month (me-
dian 10 days after onset, range 2–31), and 18 within
the first 3 months (median 26 days after onset, range
2–85). The median MOG-IgG titer at disease onset
was 1:2560 (range 160–20480; N = 18).
Persistence of serum MOG-IgG in the long-term course
In 18/22 (81.8 %) patients with follow-up samples, all
available samples were positive; in the remaining 4 pa-
tients, MOG-IgG turned negative at least once. Overall,
40 (89 %) of 45 follow-up samples from MOG-IgG-
positive patients with ON and/or myelitis were positive
after a median interval between first and last sampling
of 16.5 months (range 0–123). 13/13 (100 %) patients
were still positive for MOG-IgG 1 year after the initial
sample was taken, 8/8 (100 %) 2 years after the initial
sample, and 5/5 (100 %) after 4 years. From three pa-
tients, stored samples obtained 6.5 years, 8.5 years, and
more than 10 years before the last sample (and 13, 11,
and 8.5 years after disease onset) were available for
retrospective testing and were positive as well (first sam-
ple 1:1280 and last sample 1:640 in two patients; 1:320
and 1:160 in the third).
9/11 (81.8 %) patients that were positive for MOG-IgG
during an acute attack and had at least one available
follow-up sample obtained during remission remained
positive during remission. In one of these patients,
MOG-IgG titers temporarily fell below the cut-off once
during remission (1:80; cut-off 1:160); however, five
additional follow-up samples from the same patient
Fig. 2 Frequency and titers of MOG-IgG in 614 serum samples from 522 subjects as detected using a live-cell CBA. MOG-IgG was detected in
95/386 (24.6 %) samples in group I but was almost completely absent among 228 control samples (groups II–IV), including 89 samples from AQP4-IgG-
positive patients, 85 samples from patients with MS according to the McDonald criteria (group III), and 54 samples from healthy controls and OND
patients (group IV). While all low-titer samples (1:160–1:320) in group I were positive also in the fixed-cell CBA, the only positive control sample (from group
IV) was negative in the fixed-cell CBA, suggesting a false-positive test result. The horizontal dashed line indicates the assay-specific cut-off (> = 1:160)
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obtained during remission were all positive. Similarly,
titers were below the cut-off in two follow-up samples
(2 × 1:80) taken during remission in another patient
but were again positive (1:320) at last follow-up.
Follow-up samples obtained after plasma exchange
(PEX) or immunoadsorption (IA) were available from two
patients. In the first patient, titers declined from 1:10240 to
1:640 and subsequently disappeared completely after
treatment with intravenous methylprednisolone (IVMP),
PEX, intravenous immunoglobulins (IVIG), and oral
steroids. In the second case, titers declined from 1:5120 to
1:20 after 5 cycles of IA.
Thirty-four follow-up samples were obtained from
patients with ON and/or myelitis from group I who were
negative at first testing; all of them were negative for
MOG-IgG as well.
Impact of disease activity on MOG-IgG serum titers
36/85 (42.4 %) MOG-IgG positive samples with available
data were taken within 60 days after an acute attack.
Median MOG-IgG titers were significantly higher (1:2560)
in samples taken at the time of onset of an acute attack or
shortly thereafter (median 14 days; N = 33) than in those
taken during remission (>60 days since attack onset; 1:320;
N = 44) (p < 0.0001) (Fig. 4a). MOG-IgG titers also differed
significantly between acute attacks and remission in indi-
vidual patients (Fig. 4b). However, titers observed during
acute attacks varied both intra- and interindividually (inter-
quartile range 1:1280–3200; absolute range 160–20480),
and relatively high titers were also found in a few samples
obtained during remission (interquartile range 1:160–640;
absolute range 0–2560).
Impact of clinical presentation on MOG-IgG serum titers
during acute attacks
Median MOG-IgG titers were slightly higher during attacks
involving acute myelitis (1:2560, range 320–20480; N = 20)
than during attacks not involving acute myelitis (1:1280,
range 160–5120; N = 16; p < 0.007) (Fig. 5a). Moreover,
median titers were higher during attacks involving
Fig. 3 MOG-IgG serum titers in 386 samples from 300 patients included in group I. Diagnoses are given as provided by the referring centers.
ON and MY = optic neuritis and myelitis; mON =monophasic optic neuritis; rON = recurrent ON; LETM= longitudinally extensive transverse myelitis;
MS =multiple sclerosis; OND= other neurological disorders
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Fig. 4 MOG-IgG titers and disease activity. Titers were significantly higher during acute attacks than during remission in the total cohort (a) as
well as in individual patients with available follow-up sera (b). Horizontal lines and whiskers in panel a indicate median titers and interquartile
ranges, respectively. The median interval between samples in the right panel was 16.5 months (range 2–103). Note that panel b shows maximum
titers detected during acute attacks and minimum titers detected in follow-up sera. The difference was also significant if not the remission sample
with the lowest titer but that with the longest time interval since attack onset was used (median 1:1280 vs. 1:320; p < 0.009; not shown)
Fig. 5 MOG-IgG titers and clinical presentation. Titers were higher during attacks involving myelitis than in attacks not involving myelitis (a), and
higher during attacks involving simultaneous ON and myelitis than in attacks of isolated myelitis or isolated ON (b). The horizontal lines indicate
median titers. ON = optic neuritis; MY =myelitis
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simultaneous myelitis and ON (1:5120, range 2560–10240;
N = 7; additional brainstem encephalitis in three) than
during attacks involving either ON but no myelitis or
myelitis but no ON (1:1280 and 1:2560, respectively;
Kruskal-Wallis p < 0.009; Dunn’s post test p < 0.05 for
ON +myelitis vs. ON) (Fig. 5b).
Impact of treatment status on MOG-IgG serum titers
Precise data on the treatment status at the time of blood
sampling were available for 76/84 (90.5 %) MOG-IgG-
positive samples. 28 samples were obtained during treat-
ment with immunosuppressants (IS) or after PEX and
32 further samples were taken during or shortly after
IVMP therapy (‘treated subgroup’); another 31 samples
were taken prior to immunotherapy or in treatment-free
intervals (‘untreated subgroup’). Treatments included
IVMP, oral steroids, PEX, azathioprine, rituximab, metho-
trexate, mitoxantrone, natalizumab, and cyclosporine.
Median MOG-IgG serum titers differed significantly
between relapse (1:2560, range 160–20480; N = 23) and
remission (1:480, range 0–2560; N = 23) in patients
treated with IS and/or PEX (p < 0.0001, Fig. 6a). How-
ever, a similar difference was present also in the un-
treated subgroup (p = 0.0002; Fig. 6b), suggesting that
the decline in titers in the treated subgroup may have
not been due only to treatment effects but may also re-
flect the natural disease course. In line with that notion,
the median MOG-IgG titer in the treated subgroup did
not differ significantly from that in the untreated sub-
group, irrespective of whether all samples, only samples
taken during relapse, or only samples obtained during
remission are taken into account (data not shown).
Of note, 49/52 (94.2 %) samples were positive despite
treatment with IS/PEX and/or steroids (or 25/28 [89.3 %]
if only IS/PEX is considered). Of note, low MOG-IgG
remained detectable in all four patients treated with rituxi-
mab at the time of blood sampling (titers 1:160–1:640). In
a further patient treated with rituximab, a MOG-IgG titer
of 1:1280 was documented during a relapse and was
associated with recurrence of B cells.
Frequency of CSF MOG-IgG
In total, 17 CSF samples from 15 MOG-IgG-seropositive
patients from group I were available for testing. All but
one sample were taken during an acute attack (median
time since attack onset 10 days). Ten of those 17 CSF
samples were obtained within 30 days after disease onset
and 7 - including two follow-up samples - later in the
disease course (range 71–5406 days after onset).
Twelve out of 17 CSF samples (71 %) were positive for
MOG-IgG. The median CSF MOG-IgG titer was 1:4
(range 2–64). Individual CSF and serum results are
shown in Table 3. Median titers did no differ between
CSF samples taken at the time of the first attack (1:3)
Fig. 6 MOG-IgG titers and treatment status. While median MOG-IgG titers were lower during remission than during acute attacks in the treated
subgroup (a), a similarly significant difference was also observed in the untreated subgroup (b). By contrast, no significant difference in median
titers was observed between treated and untreated patients, neither during acute attacks nor during remission (not shown)
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and CSF samples taken during an acute attack later in
the disease course (1:3). Twelve out of 15 (80 %) patients
were positive for CSF MOG-IgG at least once. In two of
the three CSF-negative patients, lumbar puncture (LP)
was delayed (1.5, 2 and 3 weeks, respectively, after attack
onset) and was performed after or during IVMP therapy,
respectively; and in all three, LP was done for acute iso-
lated ON, a manifestation that was also associated with
lower serum titers (Fig. 5a). Among the CSF positives,
median CSF MOG-IgG titers in the initial sample taken
during an acute attack were slightly higher in patients
with acute myelitis (with or without concomitant ON
and/or brainstem encephalitis) than in patients with
acute ON (1:4 [range 2–64] vs. 1:1 [range 0–4]). An add-
itional CSF sample obtained from the only serum MOG-
IgG-positive control patient was negative for MOG-IgG.
In addition, 17 CSF samples from 17 control patients
with RRMS were tested. All of those were negative for
CSF MOG-IgG.
CSF MOG-IgG in the long-term course
Follow-up CSF samples were available from two patients.
In both cases, MOG-IgG were detectable in the CSF a
few days after disease onset, at titers of 1:64 and 1:4, re-
spectively, but not at repeat LP 51 and 21 days, respect-
ively, later. One patient had been treated with IVMP,
oral steroids, ten plasma exchanges, and IVIG in the
meantime, the other one with IVMP alone. The decline
in CSF titers was paralleled by a drop in serum titers
from 1:10240 to 1:1280 and from 1:2560 to 1:1280, re-
spectively, in these two patients.
Origin of CSF MOG-IgG
Seventeen paired CSF and serum samples were titrated to
calculate the MOG-specific AI. Evidence for intrathecal
IgG synthesis was present in none of these 17 samples: in 5
samples no MOG-specific IgG was detectable in the CSF,
and in the remaining 12 samples the MOG-specific AI was
<4 (Table 2, Fig. 7), indicating that MOG-IgG are produced
mainly in the periphery and reach the CSF by passive diffu-
sion or through a leaky blood-brain and/or blood-CSF bar-
rier. In line with that finding, CSF-restricted total IgG
oligoclonal bands were absent in 16/17 samples tested and
QIgG(total) was below Qlim in 16/17 cases, while QAlb exceeded
the age-specific reference range in 6/17 (35.3 %) samples,
indicating disruption of the blood-CSF barrier function.
MOG immunoglobulin class and subclass analyses
Twenty serum samples, including 14 MOG-IgG-positive
sera from 13 patients from group I (8 × relapse, 6 × remis-
sion) and 6 control sera from group III patients, were tested
for MOG-IgG1 using the fixed-cell CBA (Euroimmun). All
14 group I samples were positive for MOG-IgG1; by
contrast, none of 6 control sera contained MOG-IgG1
antibodies (Fig. 8). MOG-IgG1 was also present in the
CSF in 3/3 MOG-IgG serum positive patients tested.
In addition, 20 MOG-IgG-positive samples from 15 pa-
tients of group I were tested for MOG-IgM and MOG-
IgA using the fixed-cell assay. Of these, only 2 samples
(from a patient with a history of ON and myelitis) were
positive for MOG-IgM and none for MOG-IgA (Table 3).
Discussion
In 2011, some of us reported for the first time on serum
autoantibodies to full-length human MOG in patients
with NMO and related disorders [17]. This finding was
later independently confirmed by several groups [18–25,
27, 46]. However, some previous analyses were ham-
pered by low patient numbers and short follow-up times,
lack of CSF samples, and, in some cases, uncertainty re-
garding assay specificity due to low control sample num-
bers. Moreover, some studies included no Caucasian
patients. Here, we report on serological findings from a
large cohort of MOG-IgG-positive patients, almost all of
Caucasian origin. Our study demonstrates (i) that
MOG-IgG are associated with ON and myelitis in a sub-
stantial proportion of cases; (ii) that MOG-IgG and
AQP4-IgG do not usually co-exist in patients with ON
and/or myelitis, which is in support of the notion of
MOG-IgG being denoting an entity distinct from AQP4-
IgG-positive NMO spectrum disorder (NMOSD) [47];
Table 2 Lack of evidence for intrathecal IgG synthesis in 17 CSF
samples from 15
Sample
no.
MOG-IgG
titer, serum
MOG-IgG
titer, CSF
MOG-IgG
titer required
for AI >4
Evidence for
intrathecal
MOG-IgG synthesis
#1 1:10240 1:64 1:925.7 No
#2 1:2560 1:4 1:25.6 No
#3 1:320 1:2 1:2.3 No
#4 1:10240 1:16 1:152.5 No
#5 1:640 1:4 1:9 No
#6 1:2560 1:4 1:30.7 No
#7 1:10240 1:16 1:176.1 No
#8 1:2560 1:2 1:19.5 No
#9 1:320 1:2 1:3.6 No
#10 1:1280 1:2 1:9.4 No
#11 1:2560 1:4 1:25 No
#12 1:320 1:4 1:6 No
#13a 1:1280 NEG 1:17.4 No
#14 1:320 NEG 1:3.7 No
#15 1:1280 NEG 1:10.2 No
#16 1:160 NEG 1:2.1 No
#17b 1:1280 NEG 1:10.2 No
MOG-IgG seropositive patients with ON and/or myelitis. NEG negative.
aFollow-up to sample #1; b follow-up to sample #2
Jarius et al. Journal of Neuroinflammation  (2016) 13:279 Page 10 of 16
Fig. 7 MOG-specific antibody index (AI). Calculation of the MOG-specific AI in 17 paired CSF/serum samples from 15 MOG-IgG-positive patients
did not reveal evidence for intrathecal synthesis of MOG-IgG. The dotted line indicates the upper limit of the reference range (AI = 4). Inset: Reiber
diagram [40] demonstrating absence of total IgG intrathecal synthesis in 16 samples from 14 patients and presence of blood-CSF barrier dysfunction in
6/17 samples. QIgG = CSF/serum total IgG ratio; QMOG-IgG = CSF/serum MOG-IgG ratio; QAlb = CSF/serum albumin ratio; Qlim = upper reference range of
QIgG (see methods section for details)
Fig. 8 MOG-IgG1 as detected in the fixed-cell CBA. a, b Binding of serum IgG1 antibodies (from a patient with recurrent optic neuritis) to HEK293
cells transfected with human full-length MOG (a), but not to mock-transfected HEK293 cells (b). c Negative control serum (from a patient with RRMS)
binding neither to the MOG-transfected cells (upper panel) nor to the mock-transfected control cells (lower panel). Bound patient IgG1 was
detected by successive incubation with an unlabeled sheep anti-human IgG1 secondary antibody and an AlexaFluore®568-labeled donkey
anti-sheep IgG antibody (red fluorescence). Cell nuclei were stained with 4’,6-diamidino-2-phenylindole (blue fluorescence)
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(iii) that MOG-IgG are present already at the very onset
of disease, which argues against MOG-IgG being a
secondary epiphenomenon; (iv) that MOG-IgG remain
detectable in the long-term course of the disease,
indicating that the antibodies, if pathogenic, may not
only trigger the disease but remain relevant in the long
run; persisting MOG-IgG antibodies have also been de-
scribed in pediatric patients diagnosed with relapsing de-
myelinating disease [26, 28]; (v) that MOG-IgG persist
also during remission in the majority of patients, which
is similar to what has been reported in AQP4-IgG-
positive NMOSD [48], is important from a diagnostic
point of view, and suggests that MOG-IgG alone is not
sufficient to induce disease activity but other factors,
such as an increase in titers, impaired blood-CSF barrier
function (elevated QAlb was indeed noted in 12/36
(32.4 %) patients in the total cohort [36]) or T-cells, may
be required; (vi) that, similar to AQP4-IgG [48], MOG-
IgG serum titers depend on disease activity, with signifi-
cantly higher median titers during acute attacks than
during remission, both in treated and in untreated
patients, further supporting a potential pathogenic role
of MOG-IgG; (vii) that absolute serum MOG-IgG titers
vary substantially inter- and intraindividually, both dur-
ing acute disease and during remission, with no clear
cut-off for relapse induction; (viii) that MOG-IgG serum
titers may also vary significantly with clinical presenta-
tion and, in some cases, treatment; (ix) that MOG-IgG
(similar to AQP4-IgG [48]) may remain detectable even
during treatment with rituximab, which suggests a role
of long-lived plasma cells not affected by CD20-targeted
immune therapy in the production of MOG-IgG and,
given that no attacks occurred in the four patients tested
in this study while on active treatment with that drug,
that persistence of low-titer MOG-IgG does not per se
argue against the efficacy of rituximab; (x) that MOG-
IgG (like AQP4-IgG [42]) is detectable in the CSF in a
substantial number of patients during acute attacks; this
is in line with a small previous study by Dale et al., who
found MOG-IgG in 2/4 patients positive for serum
MOG-IgG [49]; (xi) that CSF MOG-IgG (just like CSF
AQP4-IgG and in line with the lack of CSF-restricted
oligoclonal bands (OCB) in most MOG-IgG-positive pa-
tients as shown in part 2 [36]) is mainly of extrathecal
origin, i.e., enters the CNS from the systemic circulation,
which may be of therapeutic relevance [42, 50–52]; (xii)
that both serum and CSF MOG-IgG belong to the
complement-activating IgG1 subclass (just as AQP4-IgG
does [53, 54] and in agreement with the presence of
complement deposits in CNS lesions in MOG-IgG-
positive patients [31, 32]), again supporting the notion of
MOG-IgG being of pathogenetic relevance; and, last but
not least, (xiii) high specificity of the live CBA used in
the present study [17] based on a very large series of
control samples, which is important since it affirms the
validity of results obtained in previous studies that have
employed that assay [25, 26, 55, 56].
Our study features strengths and limitations. Among
the strengths of the study we count (a) the high number
of MOG-IgG-positive patients with ON and/or myelitis
identified and analyzed (N = 50) compared with previous
studies (median 9 patients in [17–25, 27, 46]); (b) the
availability of a relevant number of follow-up or stored
serum samples; (c) the availability of both samples taken
at the very onset of the disease and samples taken more
than a decade thereafter; (d) the availability of a substan-
tial number (N = 17) of paired CSF and serum samples;
(e) the inclusion of a relevant number of MOG-IgG-
positive samples from untreated patients (N = 31); the
fact (f ) that virtually all patients were of Caucasian origin;
(g) that the study was performed using a multicenter (N =
11) approach, thereby reducing potential center-specific
selection biases; (h) that all MOG-IgG-positive patients
were seen at university centers with specialized neuroim-
munology departments, thereby potentially increasing
Table 3 MOG-IgG, MOG-IgG1, MOG-IgM, and MOG-IgA results
from 21 samples
No MOG-IgG1 MOG-IgG MOG-IgM MOG-IgA Disease status
1 POS POS NEG NEG Relapse
2 POS POS NEG NEG Relapse
3A POS POS NEG NEG Relapse
3B POS POS NEG NEG Remission
4 POS POS NEG NEG Remission
5 POS POS NEG NEG Remission
6 POS POS NEG NEG Remission
7 POS POS NEG NEG Remission
8 POS POS NEG NEG Relapse
9A POS POS NEG NEG Relapse
9B n.d. POS NEG NEG Remission
10A POS POS NEG NEG Relapse
10B n.d. POS NEG NEG Remission
11 n.d. POS NEG NEG Relapse
12 n.d. POS NEG NEG Remission
13 n.d. POS NEG NEG Remission
14A n.d. POS 1:1000 POS 1:20 NEG Relapse
14B n.d. POS 1:100 POS 1:10 NEG Remission
15A n.d. POS NEG NEG Remission
15B n.d. POS NEG NEG Remission
16 POS POS n.d. n.d. Relapse
17 POS POS n.d. n.d. Relapse
18 POS POS n.d. n.d. Relapse
MOG-IgG was determined using a commercial fixed CBA (cut-off 1:10). MOG-IgG1
was also present in 3/3 CSF samples from MOG-IgG1-seropositive patients
(not shown). POS positive, NEG negative, n.d not done
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diagnostic accuracy; (i) that detailed data on disease activ-
ity, clinical presentation, and treatment status at the
time of blood sampling were available for most pa-
tients; (j) that both MOG-IgG and AQP4-IgG results
were available from a relevant number of patients (N =
459); (k) that an already well-established CBA with pub-
lished sensitivity and specificity [17] was used for MOG-
IgG testing; (l) that a very large number of controls, inter-
spersed in a random pattern, were included to re-validate
the specificity of that assay (N = 222); (m) that all low-titer
samples (1:160, 1:320) were confirmed using a second,
methodologically independent CBA; and (n) that sam-
ples were evaluated by investigators not involved in
patient recruitment and blinded to all clinical data.
The limitations include a potential referral bias due to
the possibility that patients with ON and/or myelitis
may have been preferentially referred for MOG-IgG test-
ing as a consequence of the close association of MOG-
IgG with these two conditions reported in the previous
literature [18–28, 57]. However, MOG-IgG has also been
reported in, mostly pediatric, patients with acute dissemi-
nated encephalomyelitis (ADEM). Although ADEM was
considered as a differential diagnosis by the initially treat-
ing physicians in a few patients in our series (see part 2
[36] for details), our study did not specifically focus on
children or on patients with a diagnosis of ADEM. Sec-
ond, while the multicenter approach involving 11 special-
ized university departments is a potential strength as
outlined above, it also carries the potential risk of a bias
towards more severely affected patients. However, that
risk is inherent to all tertiary care studies and cannot be
completely avoided. It is important in this context that all
centers involved in the present study also have specialized
neuroinflammatory outpatient departments and that pa-
tients were recruited among both inpatients and outpa-
tients. Finally, the threshold for admission is low in
Germany, where public healthcare is free. In fact, a mild
disease course was noted in a substantial proportion of
patients (see part 2 [36] for details).
There is a discrepancy between the lack of MOG-IgG
in the MS control group in this study and the fact that
MS had been suspected by the then treating physicians
at least once in 16/45 (35.6 %) MOG-IgG positive pa-
tients, as outlined in part 2 of this series [36]. This dis-
crepancy may highlight differences in diagnostic
accuracy between carefully defined study cohorts com-
prising patients diagnosed at specialized centers and
everyday clinical practice at primary or secondary care
level. This notion is supported by the fact that MS had
been initially considered in 11 of those 16 patients des-
pite a lack of CSF-restricted OCB, a diagnostic hallmark
of MS (see part 2 [36] for details). Similarly, 10 MOG-
IgG-positive patients who formally met the 2010 McDo-
nald criteria for MS had no OCBs. Moreover, 11 patients
with suspected MS had LETM lesions, which are usually
absent in MS, and 11 did not meet Barkhof ’s MRI criteria
for MS. Finally, 6 patients in whom MS had been previ-
ously suspected did not meet the 2010 McDonald criteria
(see part 2 [36]). With the discovery of AQP4-IgG [1, 58–
60], MOG-IgG [17], N-methyl-D-aspartate receptor-IgG
[61], and a plethora of often non-paraneoplastic autoanti-
bodies identified in acute CNS inflammation over the past
decade [62–66], including in patients with primary or sec-
ondary demyelination, it becomes increasingly clear that
not all patients presenting with relapsing CNS disease of
putative autoimmune etiology have classical MS–even if
they formally meet the ‘positive’ clinicoradiological criteria
for MS [67]. In fact, 50 % of the MOG-IgG-positive pa-
tients in this study had clinical or radiological involvement
of the brain in addition to ON and/or myelitis and the
Barkhof and McDonald criteria for multiple sclerosis (MS)
were met by 15 % and 33 %, respectively, as shown in
parts 2 and 3 of this series [36, 37]. MOG-IgG-positive pa-
tients, in whom the disease starts with isolated brain or
brainstem involvement are particularly challenging [27,
36, 37, 68]. Thus more and more importance attaches to
carefully considering the ‘negative’ criterion of ruling out
other diagnoses (“no better explanation”) included in the
current diagnostic consensus criteria for MS [69]. It also
suggests that re-including CSF analysis in the diagnostic
criteria for MS, as previously recommended by us and
others [70], might help to improve diagnostic accuracy in
patients with suspected MS.
It is of clinical relevance that 15/28 (53.6 %) of the
MOG-IgG-positive patients with a history of myelitis
identified in this study had recurrent attacks of myelitis
[36]. If only patients with MOG-IgG-positive isolated
myelitis are considered, 4/6 had recurrent myelitis and
two had monophasic myelitis [36]. This suggests that
MOG-IgG testing should be considered both in patients
with monophasic and in patients with recurrent myelitis.
Similarly, MOG-IgG was found both in patients with a
single attack of ON and in patients with recurrent ON.
While treatment with IS was followed by a decline in
relapse rate in individual patients, as outlined in part 2
of this series [36], no clear effect of IS on median MOG-
IgG titers could be demonstrated in the present study.
However, this is not totally surprising: while our study is
among the largest in the field, patient numbers might still
have been too low to detect such effects, especially when
taking into account the large number of confounders such
as disease activity, attack severity, clinical presentation,
type and duration of treatment, drug-specific latency
periods, and time since attack onset. Prospective stud-
ies with fixed sampling intervals and defined treat-
ment regimens are highly warranted to assess the
effect of immunotherapy on MOG-IgG titers and its
impact on outcome and prognosis in a definite way.
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Conclusion
In summary, our study provides evidence supporting a
potential pathogenic role of MOG-IgG, and thus the
notion of MOG-IgG denoting a disease entity in its own
right, by demonstrating in the largest cohort of patients so
far: (i) a close association of MOG-IgG with a specific
clinical phenotype (i.e., ON and/or myelitis); (ii) an
increase in serum MOG-IgG titers during acute at-
tacks; (iii) the presence of MOG-IgG in the CSF in the
early phase of acute attacks in untreated patients; (iv)
the presence of complement-activating anti-MOG
antibodies of the IgG1 subclass both in the serum
and in the CSF; and (v) absence of AQP4-IgG, an
already well-established cause of optic nerve and spinal
cord damage, in MOG-IgG-positive patients. Detailed
clinical and paraclinical data were available for all 50
MOG-IgG-positive patients with ON and/or myelitis
identified in this study and are comprehensively analyzed
in parts 2 [36], 3 [37] and 4 [38] of this series.
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